Rheumatoid arthritis drug gets PBS listing

The oral therapy tofacitinib citrate has gained a PBS listing for the treatment of rheumatoid arthritis.

Marketed as Xeljanz, it is the first Janus kinase (JAK) inhibitor to be greenlighted by the PBS and will be reimbursed from 1st October.

It is listed for the treatment of moderate to severe rheumatoid arthritis in patients who have had an inadequate response to conventional DMARDs such as